申请人:Sandoz, Inc.
公开号:US04420475A1
公开(公告)日:1983-12-13
Compounds of the formula I: ##STR1## wherein each of R.sup.1, R.sup.2 and R.sup.3 is, independently, (a) alkyl having from 1 to 22 carbon atoms; or (b) of the formula ##STR2## in which m is 0, 1 or 2, and each R' and R" is independently a hydrogen atom, alkyl having from 1 to 3 carbon atoms, alkoxy having from 1 to 3 carbon atoms, or halo having an atomic weight of from about 19 to 127; and R is of an aralkyl-, phenyl- tryptophanyl- or benzo-cycloalkyl-type, are obtained by hydrogenating corresponding .alpha.-.beta. ethylenically-unsaturated analogs (II), which in turn are obtained by hydrogenating corresponding .alpha.-.beta. acetylenically-unsaturated analogs. Compounds I and II are useful as anti-atheroslerotic agents.
公式I的化合物:其中R.sup.1、R.sup.2和R.sup.3中的每一个都独立地是(a)具有1至22个碳原子的烷基;或(b)具有以下结构的化合物:其中m为0、1或2,每个R'和R"都独立地是氢原子、具有1至3个碳原子的烷基、具有1至3个碳原子的烷氧基或原子量约为19至127的卤素;而R为芳基烷基、苯基、色氨酸基或苯并环烷基类型,通过加氢对应的α-β乙烯基不饱和类似物(II)获得,而这些类似物又通过加氢对应的α-β乙炔基不饱和类似物获得。化合物I和II可用作抗动脉粥样硬化药物。